Our findings, which demonstrated prognostic value of p-eIF2α in breast cancer, are partially consistent with this previous research, because CHOP is also involved in the PERK-p-eIF2α signaling pathway and predicts better DFS in patients with breast cancer. This evidence concerns the gene EIF2A and breast cancer.